Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7381 to 7395 of 7687 results

  1. Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]

    In development [GID-TA10826] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]

    In development [GID-TA11044] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296]

    In development [GID-TA11344] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Utrasound-guided foam sclerotherapy for varicose veins (IPG314)

    This guidance has been updated and replaced by NICE interventional procedure guidance 440.

    Interventional procedures guidance
    Published
    23 August 2009

  5. Percutaneous mitral valve leaflet repair for mitral regurgitation (IPG309)

    This guidance has been updated and replaced by NICE interventional procedure guidance 649.

    Interventional procedures guidance
    Published
    26 August 2009

  6. Percutaneous endoscopic laser lumbar discectomy (IPG300)

    This guidance has been updated and replaced by NICE interventional procedures guidance 570.

    Interventional procedures guidance
    Published
    27 May 2009

  7. Antimicrobial prescribing: nebulised liposomal amikacin (ES36)

    This evidence summary has been withdrawn. An NHS England clinical commissioning policy on nebulised liposomal amikacin for the treatment of non-tuberculous mycobacterial pulmonary disease caused by mycobacterium avium complex is available.

    Evidence summary
    Published
    12 May 2021

  8. Common mental health problems: identification and pathways to care (CG123)

    We withdrew this guideline in May 2024, because all of the recommendations are now covered in other NICE guidelines, or are out of date and no longer relevant to clinical practice. For guidance on common mental health problems, see our guidelines on:

    Clinical guideline
    Published
    25 May 2011

  9. Intrapartum care for healthy women and babies - rectal examination after delivery

    Discontinued [GID-NG10395]

    NICE guideline
    Discontinued

  10. Violence and aggression: short-term management in mental health, health and community settings

    Discontinued [GID-NG10397]

    NICE guideline
    Discontinued

  11. Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]

    In development [GID-TA11569] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial cancer [ID6417]

    Discontinued [GID-TA11522]

    Technology appraisal guidance
    Discontinued

  13. Microstructural scaffold (patch) insertion without autologous cell implantation for repairing symptomatic chondral knee defects (IPG560)

    This guidance has been updated and replaced by NICE interventional procedures guidance 793.

    Interventional procedures guidance
    Published
    22 June 2016

  14. Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]

    In development [GID-TA11401] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis (TA27)

    This guidance has been replaced by NICE guideline CG59 and NICE guideline CG79.

    Technology appraisal guidance
    Published
    23 July 2001